在首个呼吸道合胞病毒季节中，尼塞韦单抗与帕利珠单抗的直接自付费用：一项比较分析。
Direct Out-of-Pocket Costs of Nirsevimab Palivizumab during the First Respiratory Syncytial Virus Season: A Comparative Analysis.
作者信息
Yun Ki Wook, Kang Dayun
机构信息
Department of Pediatrics, Seoul National University Children's Hospital, Seoul, Korea.
Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
出版信息
Infect Chemother. 2025 Jun;57(2):305-309. doi: 10.3947/ic.2025.0017. Epub 2025 Apr 15.
Abstract
Respiratory syncytial virus (RSV) remains a significant health burden in infants, with limited prevention options. Palivizumab, the monoclonal antibody (mAb) currently used for high-risk infants, requires a five-dose regimen, costing caregivers 47,260-642,000 Korean won (KRW) under the health insurance system, depending on the remaining season and infant's weight. Nirsevimab, the first approved long-acting RSV mAb, offers season-long protection with a single dose and costs 435,000-600,000 KRW. Direct cost comparisons indicate that nirsevimab might be more economical for infants born between April and November. Policy adjustments are needed to ensure equitable RSV protection through national immunization programs.
摘要
呼吸道合胞病毒（RSV）仍然是婴儿的一项重大健康负担，预防选择有限。帕利珠单抗是目前用于高危婴儿的单克隆抗体（mAb），需要五剂疗程，根据剩余季节和婴儿体重，在医疗保险制度下，护理人员需花费47,260 - 642,000韩元（KRW）。首个获批的长效RSV单克隆抗体尼塞维单抗单剂量即可提供长达一个季节的保护，费用为435,000 - 600,000韩元。直接成本比较表明，对于4月至11月出生的婴儿，尼塞维单抗可能更经济。需要进行政策调整，以通过国家免疫计划确保对RSV的公平保护。
相似文献
1
Direct Out-of-Pocket Costs of Nirsevimab Palivizumab during the First Respiratory Syncytial Virus Season: A Comparative Analysis.在首个呼吸道合胞病毒季节中，尼塞韦单抗与帕利珠单抗的直接自付费用：一项比较分析。
Infect Chemother. 2025 Jun;57(2):305-309. doi: 10.3947/ic.2025.0017. Epub 2025 Apr 15.
2
A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.对帕利珠单抗用于呼吸道合胞病毒免疫预防给药依从性的系统评价。
J Manag Care Pharm. 2010 Jan-Feb;16(1):46-58. doi: 10.18553/jmcp.2010.16.1.46.
3
Expert consensus on the burden of respiratory syncytial virus disease and the utility of nirsevimab for disease prevention and protection of infants.呼吸道合胞病毒疾病负担及尼塞韦单抗预防和保护婴儿疾病效用的专家共识。
World J Pediatr. 2025 Jun 28. doi: 10.1007/s12519-025-00926-2.
4
Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.帕利珠单抗预防高危婴儿和幼儿呼吸道合胞病毒（RSV）毛细支气管炎的免疫预防作用：亚组分析的系统评价和额外的经济建模。
Health Technol Assess. 2011 Jan;15(5):iii-iv, 1-124. doi: 10.3310/hta15050.
5
Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.用于预防婴儿和儿童呼吸道合胞病毒的单克隆抗体：系统评价和网络荟萃分析。
JAMA Netw Open. 2023 Feb 1;6(2):e230023. doi: 10.1001/jamanetworkopen.2023.0023.
6
Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study.在接受尼塞韦单抗突破性感染后呼吸道合胞病毒的基因和表型特征：一项大型、多中心、观察性、真实世界研究。
Lancet Infect Dis. 2025 Mar;25(3):301-311. doi: 10.1016/S1473-3099(24)00570-X. Epub 2024 Oct 14.
7
Cost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands.荷兰保护婴儿免受呼吸道合胞病毒感染的免疫策略的成本效益
Hum Vaccin Immunother. 2025 Dec;21(1):2521912. doi: 10.1080/21645515.2025.2521912. Epub 2025 Jun 25.
8
Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.尼赛珠单抗预防婴儿呼吸道合胞病毒住院治疗。
N Engl J Med. 2023 Dec 28;389(26):2425-2435. doi: 10.1056/NEJMoa2309189.
9
Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.帕利珠单抗预防儿童严重呼吸道合胞病毒（RSV）感染。
Cochrane Database Syst Rev. 2021 Nov 16;11(11):CD013757. doi: 10.1002/14651858.CD013757.pub2.
10
Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.使用帕利珠单抗对儿童进行呼吸道合胞病毒（RSV）免疫预防：一项系统评价与经济学评估
Health Technol Assess. 2008 Dec;12(36):iii, ix-x, 1-86. doi: 10.3310/hta12360.
本文引用的文献
1
RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing.Nirsevimab 和帕利珠单抗给药后的 RSV 中和抗体。
Pediatrics. 2024 Nov 1;154(5). doi: 10.1542/peds.2024-067174.
2
The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access.呼吸道合胞病毒疫苗和单克隆抗体领域：通向全球可及之路。
Lancet Infect Dis. 2024 Dec;24(12):e747-e761. doi: 10.1016/S1473-3099(24)00455-9. Epub 2024 Sep 23.
3
Respiratory Syncytial Virus Prevalence and Risk Factors among Healthy Term Infants, United States.呼吸道合胞病毒在健康足月婴儿中的流行情况和危险因素，美国。
Emerg Infect Dis. 2024 Oct;30(10):2199-2202. doi: 10.3201/eid3010.240609.
4
June 2024 ACIP Meeting Update: Influenza, COVID-19, RSV, and Other Vaccines.2024 年 6 月 ACIP 会议更新：流感、COVID-19、RSV 和其他疫苗。
Pediatrics. 2024 Oct 1;154(4). doi: 10.1542/peds.2024-068310.
5
Clinical Characteristics and Severity of Respiratory Syncytial Virus Infection in Korean Children during the Post-COVID-19 Pandemic Period.新冠疫情后时期韩国儿童呼吸道合胞病毒感染的临床特征与严重程度
Infect Chemother. 2024 Mar;56(1):83-87. doi: 10.3947/ic.2023.0076. Epub 2024 Mar 13.
6
Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data.2019 年导致早产儿和幼儿急性下呼吸道感染的呼吸道合胞病毒的全球疾病负担及危险因素：汇总和个体参与者数据的系统评价和荟萃分析。
Lancet. 2024 Mar 30;403(10433):1241-1253. doi: 10.1016/S0140-6736(24)00138-7. Epub 2024 Feb 14.
7
Etiology and Clinical Characteristics of Community-Acquired Pneumonia in Korean Children During the Pre-COVID-19 Period, 2015-2020.2015-2020 年新冠疫情前韩国儿童社区获得性肺炎的病因和临床特征。
J Korean Med Sci. 2023 Nov 6;38(43):e339. doi: 10.3346/jkms.2023.38.e339.
8
Respiratory syncytial virus infection and the need for immunization in Korea.韩国的呼吸道合胞病毒感染和免疫接种需求。
Expert Rev Vaccines. 2023 Jan-Dec;22(1):327-340. doi: 10.1080/14760584.2023.2189459.
9
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.尼塞利珠单抗预防早产儿和足月儿呼吸道合胞病毒下呼吸道感染的疗效，以及对伴有先天性心脏病和慢性肺部疾病的婴儿的药代动力学外推：一项随机对照试验的汇总分析。
Lancet Child Adolesc Health. 2023 Mar;7(3):180-189. doi: 10.1016/S2352-4642(22)00321-2. Epub 2023 Jan 9.
10
The 2017 Korean National Growth Charts for children and adolescents: development, improvement, and prospects.2017年韩国儿童和青少年国家生长图表：发展、改进与展望。
Korean J Pediatr. 2018 May;61(5):135-149. doi: 10.3345/kjp.2018.61.5.135. Epub 2018 May 28.
Zotero 插件